Drug intelligence / Profile preview

jinsang liyan capsule + rabeprazole

Development stage: Preclinical
Lead developer: Grand Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of Jinsang Liyan capsule and rabeprazole. Rabeprazole is a proton pump inhibitor (PPI) that decreases the amount of acid produced by the stomach by inhibiting the gastric H+, K+ATPase at the secretory surface of gastric parietal cells. The specific composition and purpose of Jinsang Liyan capsule is not fully detailed in the available information, but it appears to be a traditional Chinese medicine preparation. This combination is being studied clinically, potentially for conditions like GERD.

Brand names: Jinsang Liyan Capsule
Other names: Jinsang Liyan capsule plus rabeprazolecombination therapy

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on jinsang liyan capsule + rabeprazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jinsang liyan capsule + rabeprazole.

Explore the full profile